Compare Cytokinetics Inc (CYTK) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Kinder Morgan Inc — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Kinder Morgan Inc trades at $32.5 (market cap $72.40B). The key difference: Kinder Morgan Inc is far larger — about 6.5× Cytokinetics Inc's market cap, and Kinder Morgan Inc pays a 3.61% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | KMI | |
|---|---|---|
Market Cap | $11.12B | $72.40B |
Sector | Technology | Energy |
52-Week High | $87.26 | $34.31 |
52-Week Low | $33.23 | $25.84 |
Enterprise Value | $11.59B | $104.27B |
Dividend Yield | — | 3.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
KMI trades at $32.24, up 0.37% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.48, and revenue growth is projected to reach $17.5B in 2026. Analyst sentiment is mixed but leans positive, with 47% recommending a buy, supported by a stable dividend and a $10.1B project backlog focused on natural gas infrastructure.
The outlook for KMI is favorable, driven by rising LNG demand and contracted cash flows, though risks include commodity price volatility and high debt levels. The stock offers a solid dividend yield and growth potential from infrastructure investments, making it attractive for income and growth investors despite macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
